Adial (ADIL) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$52.0M

Net income growth (year over year)

−2555.21%

Net margin

—

Return on equity

−2011.64%

EPS (trailing twelve months)

−$17.71

Book value per share

$0.06

P/E (trailing twelve months)

—

Price to book

53.36

Debt to assets

99.46%

Payout ratio

—

Dividend yield

—

Company profile

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.

• How do I buy stock in Adial (ADIL)?

  ADIL trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.